As many of our readers may be aware, the “right to try” treatments using investigational new drugs outside of the clinical trials processes required by drug developers and overseen by the US Food and Drug Administration is a current “hot topic” on Capitol Hill. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: "right to try", investigational, Legislation, off-label, Treatment, unapproved | Leave a comment »
On Friday last week, US regulators recommended that oral ketoconazole should no longer be used as a first-line treatment for fungal infections whereas European regulators recommended a complete suspension of marketing for all oral ketoconazole-containing drugs. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ketoconazole, off-label | 1 Comment »
As many in the prostate cancer community will be aware, there has been a major battle ongoing over whether the drug bevacizumab (Avastin) should continue to be approved by the U.S. Food & Drug Administration (FDA) for the treatment of women with metastatic breast cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: Centers for Medicare and Medicaid Services, CMS, coverage, off-label | Leave a comment »
